Cyclooxygenase 2: Its regulation, role and impact in airway inflammation

Clinical and Experimental Allergy

Volumn 46, Issue 3, 2016, Pages 397-410

  Rumzhum, N N ^a   Ammit, A J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BRADYKININ; CYCLOOXYGENASE 2; CYTOKINE; LIGAND; METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROSTANOID; SPHINGOSINE 1 PHOSPHATE; TOLL LIKE RECEPTOR; ANTIINFLAMMATORY AGENT; AUTACOID; CYCLOOXYGENASE 2 INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CELL MIGRATION; CELL PROLIFERATION; COUGHING; DESENSITIZATION; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MUCUS SECRETION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; RESPIRATORY TRACT DISEASES; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; RESPIRATORY TRACT DISEASES; SIGNAL TRANSDUCTION;

EID: 84959047042     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12697     Document Type: Review

References (161)

1. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302(Pt 3):723-7.
2. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007; 46:108-25.
3. Harper KA, Tyson-Capper AJ. Complexity of COX-2 gene regulation. Biochem Soc Trans 2008; 36:543-5.
4. Sawaoka H, Dixon DA, Oates JA, Boutaud O. Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J Biol Chem 2003; 278:13928-35.
5. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. J Biol Chem 2000; 275:11750-7.
6. Mukhopadhyay D, Houchen CW, Kennedy S, Dieckgraefe BK, Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 2003; 11:113-26.
7. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003; 278:37637-47.
8. Erkinheimo TL, Lassus H, Sivula A et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003; 63:7591-4.
9. Doller A, Gauer S, Sobkowiak E, Geiger H, Pfeilschifter J, Eberhardt W. Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R. Am J Pathol 2009; 174:1252-63.
10. Hall-Pogar T, Zhang H, Tian B, Lutz CS. Alternative polyadenylation of cyclooxygenase-2. Nucleic Acids Res 2005; 33:2565-79.
11. Hall-Pogar T, Liang S, Hague LK, Lutz CS. Specific trans-acting proteins interact with auxiliary RNA polyadenylation elements in the COX-2 3'-UTR. RNA 2007; 13:1103-15.
12. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA 1989; 86:1657-61.
13. Sully G, Dean JL, Wait R et al. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1). Biochem J 2004; 377:629-39.
14. Dixon DA, Balch GC, Kedersha N et al. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med 2003; 198:475-81.
15. Phillips K, Kedersha N, Shen L, Blackshear PJ, Anderson P. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci USA 2004; 101:2011-6.
16. Cok SJ, Morrison AR. The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001; 276:23179-85.
17. Sureban SM, Ramalingam S, Natarajan G et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 2008; 27:4544-56.
18. Anant S, Murmu N, Houchen CW et al. Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology 2004; 127:1139-49.
19. Kishor A, Tandukar B, Ly YV et al. Hsp70 is a novel posttranscriptional regulator of gene expression that binds and stabilizes selected mRNAs containing AU-rich elements. Mol Cell Biol 2013; 33:71-84.
20. Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett 1998; 439:75-80.
21. Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999; 274:264-9.
22. Zhang Z, Sheng H, Shao J, Beauchamp RD, DuBois RN. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia 2000; 2:523-30.
23. Jang BC, Sanchez T, Schaefers HJ et al. Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem 2000; 275:39507-15.
24. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001; 21:771-80.
25. Chakrabarty A, Tranguch S, Daikoku T, Jensen K, Furneaux H, Dey SK. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci USA 2007; 104:15144-9.
26. Agra Andrieu N, Motino O, Mayoral R et al. Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells. PLoS ONE 2012; 7:e50935.
27. Cheng Z, Qiu S, Jiang L et al. MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1. J Clin Immunol 2013; 33:567-76.
28. Comer BS, Camoretti-Mercado B, Kogut PC, Halayko AJ, Solway J, Gerthoffer WT. MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2014; 307:L727-34.
29. Comer BS, Camoretti-Mercado B, Kogut PC, Halayko AJ, Solway J, Gerthoffer WT. Cyclooxygenase-2 and microRNA-155 expression are elevated in asthmatic airway smooth muscle cells. Am J Respir Cell Mol Biol 2015; 52:438-47.
30. Reiger MK, DeWitt DL, Schindler MS, Smith WL. Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. Arch Biochem Biophys 1993; 301:439-44.
31. Otto JC, DeWitt DL, Smith WL. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 1993; 268:18234-42.
32. Yuan C, Smith WL. A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus. J Biol Chem 2015; 290:5606-20.
33. Xiao G, Chen W, Kulmacz RJ. Comparison of structural stabilities of prostaglandin H synthase-1 and -2. J Biol Chem 1998; 273:6801-11.
34. Spencer AG, Thuresson E, Otto JC et al. The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J Biol Chem 1999; 274:32936-42.
35. Yuan C, Rieke CJ, Rimon G, Wingerd BA, Smith WL. Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci USA 2006; 103:6142-7.
36. Mbonye UR, Yuan C, Harris CE et al. Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 2008; 283:8611-23.
37. Wada M, Saunders TL, Morrow J et al. Two pathways for cyclooxygenase-2 protein degradation in vivo. J Biol Chem 2009; 284:30742-53.
38. Mbonye UR, Song I. Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep 2009; 42:552-60.
39. Mevkh AT, Miroshnikov KA, Igumnova ND, Varfolomeev SD. Prostaglandin H synthase. Inactivation of the enzyme in the course of catalysis is accompanied by fast and dramatic changes in protein structure. FEBS Lett 1993; 321:205-8.
40. Song I, Ball TM, Smith WL. Different suicide inactivation processes for the peroxidase and cyclooxygenase activities of prostaglandin endoperoxide H synthase-1. Biochem Biophys Res Commun 2001; 289:869-75.
41. Mbonye UR, Wada M, Rieke CJ, Tang HY, Dewitt DL, Smith WL. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006; 281:35770-8.
42. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 2000; 374:325-33.
43. Figueiredo-Pereira ME, Li Z, Jansen M, Rockwell P. N-acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells. J Biol Chem 2002; 277:25283-9.
44. Neuss H, Huang X, Hetfeld BK et al. The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs. J Mol Med (Berl) 2007; 85:961-70.
45. Chen SF, Wu CH, Lee YM et al. Caveolin-1 interacts with Derlin-1 and promotes ubiquitination and degradation of cyclooxygenase-2 via collaboration with p97 complex. J Biol Chem 2013; 288:33462-9.
46. Singh M, Chaudhry P, Parent S, Asselin E. Ubiquitin-proteasomal degradation of COX-2 in TGF-beta stimulated human endometrial cells is mediated through endoplasmic reticulum mannosidase I. Endocrinology 2012; 153:426-37.
47. Chen SF, Liou JY, Huang TY et al. Caveolin-1 facilitates cyclooxygenase-2 protein degradation. J Cell Biochem 2010; 109:356-62.
48. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992; 89:958-67.
49. Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993; 147:291-5.
50. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996; 154:1061-6.
51. Mitchell JA, Belvisi MG, Akarasereenont P et al. Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994; 113:1008-14.
52. Belvisi MG, Saunders MA, el Haddad B et al. Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol 1997; 120:910-6.
53. Pang L, Knox AJ. Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997; 121:579-87.
54. Petkova DK, Pang L, Range SP, Holland E, Knox AJ. Immunocytochemical localization of cyclo-oxygenase isoforms in cultured human airway structural cells. Clin Exp Allergy 1999; 29:965-72.
55. Bradbury DA, Newton R, Zhu YM et al. Effect of bradykinin, TGF-beta1, IL-1beta, and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002; 283:L717-25.
56. Nie M, Pang L, Inoue H, Knox AJ. Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1beta in human airway smooth muscle cells: involvement of different promoter elements, transcription factors, and histone h4 acetylation. Mol Cell Biol 2003; 23:9233-44.
57. Newton R, Kuitert LM, Slater DM, Adcock IM, Barnes PJ. Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci 1997; 60:67-78.
58. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun 1997; 237:28-32.
59. Newton R, Stevens DA, Hart LA, Lindsay M, Adcock IM, Barnes PJ. Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. FEBS Lett 1997; 418:135-8.
60. Newton R, Seybold J, Liu SF, Barnes PJ. Alternate COX-2 transcripts are differentially regulated: implications for post-transcriptional control. Biochem Biophys Res Commun 1997; 234:85-9.
61. Newton R, Seybold J, Kuitert LM, Bergmann M, Barnes PJ. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 1998; 273:32312-21.
62. Laporte JD, Moore PE, Abraham JH et al. Role of ERK MAP kinases in responses of cultured human airway smooth muscle cells to IL-1beta. Am J Physiol 1999; 277:L943-51.
63. Laporte JD, Moore PE, Lahiri T, Schwartzman IN, Panettieri RA Jr, Shore SA. p38 MAP kinase regulates IL-1 beta responses in cultured airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 279:L932-41.
64. Newton R, Cambridge L, Hart LA, Stevens DA, Lindsay MA, Barnes PJ. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br J Pharmacol 2000; 130:1353-61.
65. Alkhouri H, Rumzhum NN, Rahman MM et al. TLR2 activation causes tachyphylaxis to beta2 -agonists in vitro and ex vivo: modelling bacterial exacerbation. Allergy 2014; 69:1215-22.
66. Rumzhum NN, Rahman MM, Oliver BG, Ammit AJ. Effect of Sphingosine 1-Phosphate on Cyclo-Oxygenase-2 Expression, Prostaglandin E2 Secretion, and β2-Adrenergic Receptor Desensitization. Am J Respir Cell Mol Biol 2016; 54:128-35.
67. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114:1335-42.
68. Rumzhum NN, Patel BS, Prabhala P, Gelissen IC, Oliver BG, Ammit AJ. IL-17A increases TNF?-induced COX-2 protein stability and augments PGE2 secretion from airway smooth muscle cells: impact on β2 -adrenergic receptor desensitization. Allergy. 2015 Nov 25. doi: 10.1111/all.12810. [Epub ahead of print]
69. Van Ly D, Faiz A, Jenkins C et al. Characterising the mechanism of airway smooth muscle beta2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS ONE 2013; 8:e56058.
70. Kirkby NS, Zaiss AK, Wright WR et al. Differential COX-2 induction by viral and bacterial PAMPs: consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. Biochem Biophys Res Commun 2013; 438:249-56.
71. Christiansen SC, Proud D, Cochrane CG. Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest 1987; 79:188-97.
72. Pang L, Knox AJ. PGE2 release by bradykinin in human airway smooth muscle cells: involvement of cyclooxygenase-2 induction. Am J Physiol 1997; 273:L1132-40.
73. Pang L, Knox AJ. Bradykinin stimulates IL-8 production in cultured human airway smooth muscle cells: role of cyclooxygenase products. J Immunol 1998; 161:2509-15.
74. Bradbury DA, Corbett L, Knox AJ. PI 3-kinase and MAP kinase regulate bradykinin induced prostaglandin E2 release in human pulmonary artery by modulating COX-2 activity. FEBS Lett 2004; 560:30-4.
75. Foronjy RF, Mirochnitchenko O, Propokenko O et al. Superoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice. Am J Respir Crit Care Med 2006; 173:623-31.
76. Kinnula VL. Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax 2005; 60:693-700.
77. Martey CA, Pollock SJ, Turner CK et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004; 287:L981-91.
78. Lin CC, Lee IT, Yang YL, Lee CW, Kou YR, Yang CM. Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: role of TLR4-dependent NADPH oxidase activation. Free Radic Biol Med 2010; 48:240-54.
79. Cheng SE, Lee IT, Lin CC, Wu WL, Hsiao LD, Yang CM. ATP mediates NADPH oxidase/ROS generation and COX-2/PGE2 expression in A549 cells: role of P2 receptor-dependent STAT3 activation. PLoS ONE 2013; 8:e54125.
80. Watkins DN, Garlepp MJ, Thompson PJ. Regulation of the inducible cyclo-oxygenase pathway in human cultured airway epithelial (A549) cells by nitric oxide. Br J Pharmacol 1997; 121:1482-8.
81. Ammit AJ, Hastie AT, Edsall LC et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J 2001; 15:1212-4.
82. Nodai A, Machida T, Izumi S et al. Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci 2007; 80:1768-76.
83. Fuerst E, Foster HR, Ward JP, Corrigan CJ, Cousins DJ, Woszczek G. Sphingosine-1-phosphate induces pro-remodelling response in airway smooth muscle cells. Allergy 2014; 69:1531-9.
84. Hsu CK, Lee IT, Lin CC, Hsiao LD, Yang CM. Sphingosine-1-phosphate mediates COX-2 expression and PGE2 /IL-6 secretion via c-Src-dependent AP-1 activation. J Cell Physiol 2015; 230:702-15.
85. Pang L, Nie M, Corbett L, Knox AJ. Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol 2003; 170:1043-51.
86. Bonazzi A, Bolla M, Buccellati C et al. Effect of endogenous and exogenous prostaglandin E(2) on interleukin-1 beta-induced cyclooxygenase-2 expression in human airway smooth-muscle cells. Am J Respir Crit Care Med 2000; 162:2272-7.
87. Chambers LS, Black JL, Ge Q et al. PAR-2 activation, PGE2, and COX-2 in human asthmatic and nonasthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285:L619-27.
88. Nasser SM, Pfister R, Christie PE et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153:90-6.
89. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58:585-8.
90. Chen Y, Chen P, Hanaoka M, Droma Y, Kubo K. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 2008; 13:1014-21.
91. Claar D, Hartert TV, Peebles RS. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med 2015; 9:55-72.
92. Demoly P, Jaffuel D, Lequeux N et al. Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics. Am J Respir Crit Care Med 1997; 155:670-5.
93. Cho W, Kim Y, Jeoung DI, Kim YM, Choe J. IL-4 and IL-13 suppress prostaglandins production in human follicular dendritic cells by repressing COX-2 and mPGES-1 expression through JAK1 and STAT6. Mol Immunol 2011; 48:966-72.
94. Pang L, Holland E, Knox AJ. Impaired cAMP production in human airway smooth muscle cells by bradykinin: role of cyclooxygenase products. Am J Physiol 1998; 275:L322-9.
95. Hall IP, Daykin K, Widdop S. β2-adrenoceptor desensitization in cultured human airway smooth muscle. Clin Sci 1993; 84:151-7.
96. Penn RB, Panettieri RA Jr, Benovic JL. Mechanisms of acute desensitization of the β2AR-adenylyl cyclase pathway in human airway smooth muscle. Am J Respir Cell Mol Biol 1998; 19:338-48.
97. Laporte JD, Moore PE, Panettieri RA, Moeller W, Heyder J, Shore SA. Prostanoids mediate IL-1beta-induced beta-adrenergic hyporesponsiveness in human airway smooth muscle cells. Am J Physiol 1998; 275:L491-501.
98. Pang L, Holland E, Knox AJ. Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline. Br J Pharmacol 1998; 125:1320-8.
99. Pascual RM, Billington CK, Hall IP et al. Mechanisms of cytokine effects on G protein-coupled receptor-mediated signaling in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2001; 281:L1425-35.
100. Shore SA, Moore PE. Regulation of beta-adrenergic responses in airway smooth muscle. Respir Physiol Neurobiol 2003; 137:179-95.
101. Billington CK, Ojo OO, Penn RB, Ito S. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther 2013; 26:112-20.
102. Trian T, Moir LM, Ge Q et al. Rhinovirus-induced exacerbations of asthma: how is the beta2-adrenoceptor implicated? Am J Respir Cell Mol Biol 2010; 43:227-33.
103. McGraw DW, Mihlbachler KA, Schwarb MR et al. Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 2006; 116:1400-9.
104. Marom Z, Shelhamer JH, Kaliner M. Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airways in vitro. J Clin Invest 1981; 67:1695-702.
105. Kim YD, Kwon EJ, Park DW, Song SY, Yoon SK, Baek SH. Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells. Mol Pharmacol 2002; 62:1112-8.
106. Gray T, Nettesheim P, Loftin C et al. Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol 2004; 66:337-46.
107. Cataldo D, Munaut C, Noel A et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123:259-67.
108. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117:684-94.
109. Kawakami Y, Uchiyama K, Irie T, Murao M. Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators. Eur J Clin Pharmacol 1973; 6:127-32.
110. Nasra J, Belvisi MG. Modulation of sensory nerve function and the cough reflex: understanding disease pathogenesis. Pharmacol Ther 2009; 124:354-75.
111. Maher SA, Belvisi MG. Prostanoids and the cough reflex. Lung 2010; 188(Suppl. 1):S9-12.
112. Maher SA, Dubuis ED, Belvisi MG. G-protein coupled receptors regulating cough. Curr Opin Pharmacol 2011; 11:248-53.
113. Maher SA, Birrell MA, Belvisi MG. Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med 2009; 180:923-8.
114. Maher SA, Birrell MA, Adcock JJ et al. Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events. Eur Respir J 2015; 45:1108-18.
115. Barile FA, Ripley-Rouzier C, Siddiqi ZE, Bienkowski RS. Effects of prostaglandin E1 on collagen production and degradation in human fetal lung fibroblasts. Arch Biochem Biophys 1988; 265:441-6.
116. Johnson PR, Armour CL, Carey D, Black JL. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am J Physiol 1995; 269:L514-9.
117. Belvisi MG, Saunders M, Yacoub M, Mitchell JA. Expression of cyclo-oxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth. Br J Pharmacol 1998; 125:1102-8.
118. Vlahos R, Stewart AG. Interleukin-1alpha and tumour necrosis factor-alpha modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate. Br J Pharmacol 1999; 126:1315-24.
119. Goncharova EA, Billington CK, Irani C et al. Cyclic AMP-mobilizing agents and glucocorticoids modulate human smooth muscle cell migration. Am J Respir Cell Mol Biol 2003; 29:19-27.
120. Nair P, Radford K, Fanat A, Janssen LJ, Peters-Golden M, Cox PG. The effects of leptin on airway smooth muscle responses. Am J Respir Cell Mol Biol 2008; 39:475-81.
121. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995; 345:436-8.
122. Rosenthale ME, Dervinis A, Begany AJ, Lapidus M, Gluckman MI. Bronchodilator activity of prostaglandin E2 when administered by aerosol to 3 species. Experientia 1970; 26:1119-21.
123. Cuthbert MF. Effect on airways resistance of prostaglandin E1 given by aerosol to healthy and asthmatic volunteers. Br Med J 1969; 4:723-6.
124. Smith AP, Cuthbert MF, Dunlop LS. Effects of inhaled prostaglandins E1, E2, and F2alpha on the airway resistance of healthy and asthmatic man. Clin Sci Mol Med 1975; 48:421-30.
125. Gardiner PJ. The effects of some natural prostaglandins on isolated human circular bronchial muscle. Prostaglandins 1975; 10:607-16.
126. Melillo E, Woolley KL, Manning PJ, Watson RM, O'Byrne PM. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994; 149:1138-41.
127. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999; 159:31-6.
128. Lazzeri N, Belvisi MG, Patel HJ, Chung KF, Yacoub MH, Mitchell JA. RANTES release by human airway smooth muscle: effects of prostaglandin E(2) and fenoterol. Eur J Pharmacol 2001; 433:231-5.
129. Ammit AJ, Hoffman RK, Amrani Y et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate. Am J Respir Cell Mol Biol 2000; 23:794-802.
130. Kaur M, Holden NS, Wilson SM et al. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 2008; 295:L505-14.
131. MacKenzie KF, Clark K, Naqvi S et al. PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol 2013; 190:565-77.
132. Lahiri T, Laporte JD, Moore PE, Panettieri RA Jr, Shore SA. Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1225-32.
133. Knox AJ, Corbett L, Stocks J, Holland E, Zhu YM, Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J 2001; 15:2480-8.
134. Stocks J, Bradbury D, Corbett L, Pang L, Knox AJ. Cytokines upregulate vascular endothelial growth factor secretion by human airway smooth muscle cells: role of endogenous prostanoids. FEBS Lett 2005; 579:2551-6.
135. Laidlaw TM, Boyce JA. Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am 2013; 33:195-210.
136. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015; 135:676-681.e671.
137. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99:13-21.
138. Christie PE, Tagari P, Ford-Hutchinson AW et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143:1025-9.
139. Sestini P, Armetti L, Gambaro G et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153:572-5.
140. Schäfer D, Maune S. Pathogenic mechanisms and in vitro diagnosis of AERD. J Allergy 2012; 2012:789232.
141. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 2002; 62:250-6.
142. Luo M, Jones SM, Flamand N, Aronoff DM, Peters-Golden M, Brock TG. Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase. J Biol Chem 2005; 280:40609-16.
143. Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 2006; 147:707-13.
144. Sturm EM, Schratl P, Schuligoi R et al. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol 2008; 181:7273-83.
145. Picado C, Fernandez-Morata JC, Juan M et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999; 160:291-6.
146. Cheong HS, Park SM, Kim MO et al. Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics. Allergy 2011; 66:637-44.
147. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996; 153:567-71.
148. Lundequist A, Nallamshetty SN, Xing W et al. Prostaglandin E2 exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation. J Immunol 2010; 184:433-41.
149. Liu T, Laidlaw TM, Katz HR, Boyce JA. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci 2013; 110:16987-92.
150. Liu T, Garofalo D, Feng C et al. Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors. J Immunol 2015; 194:5061-8.
151. Liu T, Kanaoka Y, Barrett NA et al. Aspirin-exacerbated respiratory disease involves a Cysteinyl Leukotriene-Driven IL-33 - mediated mast cell activation pathway. J Immunol 2015; 195:3537-45.
152. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015; 135:245-52.
153. Corrigan CJ, Napoli RL, Meng Q et al. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma. J Allergy Clin Immunol 2012; 129:1636-46.
154. Cahill KN, Raby BA, Zhou X et al. Impaired EP expression causes resistance to prostaglandin E in nasal polyp fibroblasts from subjects with AERD. Am J Respir Cell Mol Biol 2015; 54:34-40.
155. Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014; 134:40-45.e10.
156. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015; 3:711-8.
157. Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, Belvisi MG. EP4 receptor as a new target for bronchodilator therapy. Thorax 2011; 66:1029-35.
158. Birrell MA, Maher SA, Buckley J et al. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol 2013; 168:129-38.
159. Birrell MA, Maher SA, Dekkak B et al. Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. Thorax 2015; 70:740-7.
160. Serra-Pages M, Torres R, Plaza J et al. Activation of the Prostaglandin E2 receptor EP2 prevents house dust mite-induced airway hyperresponsiveness and inflammation by restraining mast cells' activity. Clin Exp Allergy 2015; 45:1590-600.
161. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120.